| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 31,768 | 13,156 |
| Proceeds from issuance of common stock under benefit plans, net | 365 | 301 |
| Net cash provided by financing activities | 365 | 301 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -11,134 | -15,620 |
| Cash and cash equivalents at beginning of period | 59,413 | - |
| Cash and cash equivalents at end of period | 48,279 | - |
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)